Joe is a co-founder of Enliven Therapeutics and serves as the Chief Scientific Officer. Prior to co-founding Enliven, Joe served as Vice President of Medicinal Chemistry and DMPK at Biogen, a biotechnology company focused on therapies for neurological diseases. He also worked as an Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma. He began his pharmaceutical career as a medicinal chemist at Pfizer Groton.
Joe has experience in multiple therapeutic areas, including antibiotics, immunology, cancer, and neuroscience. He has led or been a key scientific contributor to over 30 programs, which has resulted in the discovery of more than 15 clinical candidates, most notably: Koselugo™ (selumetinib), Mektovi® (binimetinib), Tukysa® (tucatinib), crenolanib, BIIB091, varlitinib tosilate, filanesib, and motolimod. He is a co-inventor or co-author on over 230 issued patents and peer-reviewed publications.
Joe earned a Ph.D. in Chemistry from the University of California, Berkeley and a B.S. in Chemistry from the College of William and Mary.
What is Joseph P. Lyssikatos' net worth?
The estimated net worth of Joseph P. Lyssikatos is at least $19.32 million as of November 19th, 2025. Dr. Lyssikatos owns 902,688 shares of Enliven Therapeutics stock worth more than $19,317,523 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Lyssikatos may own. Additionally, Dr. Lyssikatos receives an annual salary of $632,670.00 as Co-founder, Chief Scientific Officer at Enliven Therapeutics. Learn More about Joseph P. Lyssikatos' net worth.
How old is Joseph P. Lyssikatos?
Dr. Lyssikatos is currently 59 years old. There are 5 older executives and no younger executives at Enliven Therapeutics. The oldest executive at Enliven Therapeutics is Dr. Helen Louise Collins M.D., Chief Medical Officer, who is 61 years old. Learn More on Joseph P. Lyssikatos' age.
What is Joseph P. Lyssikatos' salary?
As the Co-founder, Chief Scientific Officer of Enliven Therapeutics, Inc., Dr. Lyssikatos earns $632,670.00 per year. There are 2 executives that earn more than Dr. Lyssikatos. The highest earning executive at Enliven Therapeutics is Mr. Samuel S. Kintz M.B.A., Co-Founder, CEO, Secretary & Director, who commands a salary of $866,410.00 per year. Learn More on Joseph P. Lyssikatos' salary.
How do I contact Joseph P. Lyssikatos?
Has Joseph P. Lyssikatos been buying or selling shares of Enliven Therapeutics?
Over the course of the past ninety days, Joseph P. Lyssikatos has sold $555,125.00 in Enliven Therapeutics stock. Most recently, Joseph P. Lyssikatos sold 12,500 shares of the business's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $22.33, for a transaction totalling $279,125.00. Following the completion of the sale, the insider now directly owns 902,688 shares of the company's stock, valued at $20,157,023.04. Learn More on Joseph P. Lyssikatos' trading history.
Who are Enliven Therapeutics' active insiders?
Are insiders buying or selling shares of Enliven Therapeutics?
In the last twelve months, insiders at the sold shares 55 times. They sold a total of 344,713 shares worth more than $7,118,196.83. The most recent insider tranaction occured on November, 19th when insider Joseph P Lyssikatos sold 12,500 shares worth more than $279,125.00. Insiders at Enliven Therapeutics own 25.9% of the company.
Learn More about insider trades at Enliven Therapeutics. Information on this page was last updated on 11/19/2025.
